1. Home
  2. FT vs GBIO Comparison

FT vs GBIO Comparison

Compare FT & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FT
  • GBIO
  • Stock Information
  • Founded
  • FT 1988
  • GBIO 2016
  • Country
  • FT United States
  • GBIO United States
  • Employees
  • FT N/A
  • GBIO N/A
  • Industry
  • FT Trusts Except Educational Religious and Charitable
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FT Finance
  • GBIO Health Care
  • Exchange
  • FT Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • FT 185.7M
  • GBIO 64.8M
  • IPO Year
  • FT N/A
  • GBIO 2020
  • Fundamental
  • Price
  • FT $7.29
  • GBIO $0.88
  • Analyst Decision
  • FT
  • GBIO Strong Buy
  • Analyst Count
  • FT 0
  • GBIO 2
  • Target Price
  • FT N/A
  • GBIO $6.50
  • AVG Volume (30 Days)
  • FT 63.0K
  • GBIO 581.0K
  • Earning Date
  • FT 01-01-0001
  • GBIO 03-05-2025
  • Dividend Yield
  • FT 7.85%
  • GBIO N/A
  • EPS Growth
  • FT N/A
  • GBIO N/A
  • EPS
  • FT N/A
  • GBIO N/A
  • Revenue
  • FT N/A
  • GBIO $18,582,000.00
  • Revenue This Year
  • FT N/A
  • GBIO $212.74
  • Revenue Next Year
  • FT N/A
  • GBIO N/A
  • P/E Ratio
  • FT N/A
  • GBIO N/A
  • Revenue Growth
  • FT N/A
  • GBIO 514.08
  • 52 Week Low
  • FT $5.97
  • GBIO $0.75
  • 52 Week High
  • FT $7.23
  • GBIO $4.65
  • Technical
  • Relative Strength Index (RSI)
  • FT 40.30
  • GBIO 28.66
  • Support Level
  • FT $7.19
  • GBIO $0.85
  • Resistance Level
  • FT $7.35
  • GBIO $1.01
  • Average True Range (ATR)
  • FT 0.09
  • GBIO 0.12
  • MACD
  • FT 0.00
  • GBIO 0.00
  • Stochastic Oscillator
  • FT 43.75
  • GBIO 7.50

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: